Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Strain-based vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention Strategy in Patients With Breast Cancer Who Treated With Adjuvant Trastuzumab

NCT04429633 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT04429633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04429633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Strain-based vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention Strategy in Patients With Breast Cancer Who Treated With Adjuvant Trastuzumab
Lead sponsor
Samsung Medical Center
Phase
Not applicable
Overall status
Unknown status
Start date
July 19, 2019
Completion date
July 18, 2023
Enrollment
136 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adjuvant, breast cancer, cardiotoxicity, prevention, trastuzumab